Indications for ALOXI:
Prevention of acute nausea and vomiting due to initial and repeat courses of moderately and highly emetogenic chemotherapy in adults. Prevention of delayed nausea and vomiting due to initial and repeat courses of moderately emetogenic chemotherapy in adults. Prevention of acute nausea and vomiting due to initial and repeat courses of emetogenic chemotherapy, including highly emetogenic cancer chemotherapy, in children 1 month–<17yrs. Prevention of post-op nausea and vomiting for up to 24hrs after surgery in adults.
≥17yrs: give 30 mins prior to chemotherapy. 0.25mg IV as a single-dose over 30 secs. Post-op: give immediately before anesthesia induction. 0.075mg IV over 10 secs.
<1 month: not established. 1 month–<17yrs: give 30 mins prior to chemotherapy. 0.02mg/kg IV as a single-dose over 15 mins; max 1.5mg/dose.
Pregnancy (Cat.B). Nursing mothers: not recommended.
Selective 5-HT3 receptor antagonist.
Headache, constipation, bradycardia, QT prolongation, diarrhea, dizziness, tachycardia, hypotension.
Single-use vial (0.075mg/1.5mL)—5; (0.25mg/5mL)—1